drugset
drugset / Trial / NCT06780033

A Study to Evaluate ART101 in Adult Participants With Hypertension

NCT06780033 ↗

Phase 1 Terminated 1 enrolled Arnatar Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase 1, first-in-human, randomized, double-blind, placebo-controlled, study to assess the safety, tolerability, Pharmacokinetics (PK), and pharmacodynamics (PD) of a single dose of ART101 administered via subcutaneous injection to hypertensive adult participants. An anticipated 5 dose cohorts (one as optional) with maximum of 40 participants will be randomized in SAD study.

Timeline

Start
2025-03-17
Primary completion
2025-04-30
Completion
2025-04-30

Outcome

Outcome not reported

Stopped: “At Sponsor's Request”

Drugs

EvaluationDrugModalityDoseRoute
Subject ART101 Unknown 20 mg Subcutaneous
Subject ART101 Unknown 60 mg Subcutaneous
Subject ART101 Unknown 150 mg Subcutaneous
Subject ART101 Unknown 300 mg Subcutaneous
Subject ART101 Unknown 500 mg Subcutaneous

Indications

hypertensive disorder